Talk:Lamivudine

Patent expiry

According to GSK's annual report, the patent expires 2010 in US and 2011 in Europe. Unless anyone can find a source for the 2016 date in the article, I'll change it. 203.214.62.109 15:04, 2 June 2007 (UTC)

Well as results search i dont believe in myths Thandorekhuzie704 (talk) 16:09, 14 December 2017 (UTC)

NPOV issue?

"GlaxoSmithKline sought to perpetuate the fiction that..." seems rather polemic in tone. Need to look into the history of that edit. Ccreitz 18:50, 5 June 2007 (UTC)

structure stereochemistry

appears incorrect to me, the base and 5'CH2OH should be on the same side of the ring 155.91.28.231 13:18, 12 September 2007 (UTC)

I've uploaded a new structure. Thank you for bringing this up. Fvasconcellos (t·c) 13:43, 12 September 2007 (UTC)

I'm afraid it's still incorrect. The current picture has D-stereochemistry, while lamivudine has the nonnatural L-stereochemistry. —Preceding unsigned comment added by 155.91.28.231 (talk) 18:16, 12 September 2007 (UTC)

Got it. Fvasconcellos (t·c) 19:43, 12 September 2007 (UTC)

I second it. The stereochemistry is wrong, this is the enantiomer of the true structure. Tgunda (talk) 07:36, 23 September 2014 (UTC)

It is still wrong I am going to try to correct it edit:correctedSatanorsanta (talk) 15:10, 9 July 2015 (UTC)

minor edit

"Physical Interaction with Tenofovir DF" was showing up with funny lines i just edited it without changing any content. —Preceding unsigned comment added by 82.44.253.212 (talk) 04:37, 24 February 2008 (UTC)

help

is there any problem if HBV patient has taken Ziffix 100mg tab twice? And as known its given once daily . Need urgent helping relply on my mail its (ehabalhkeem@yahoo.com) thanking you —Preceding unsigned comment added by 188.132.71.152 (talk) 03:50, 6 July 2009 (UTC)

A friend is being treated with lamivudine for HIV - that article says it is NEVER used on it's own. Does anyone know for sure? — Preceding unsigned comment added by 41.146.220.209 (talk) 08:34, 14 November 2012 (UTC)

Use in Ebola Virus Disease

News reports are stating a doctor has successfully treated Ebola patients with Lamivudine Blacknail (talk) 02:53, 28 September 2014 (UTC)

Citations

Most of this article is unreferenced. For example, the first citation comes about halfway through.Wawawemn (talk) 14:47, 13 October 2011 (UTC)

The following is unsourced WP:OR - moving it here per WP:VERIFY

Dr. Cheng in collaboration with R.F. Schinazi and D.C. Liotta first reported the anti-hepatitis B virus (HBV) activity of Lamivudine in cell culture which eventually led to the first oral antiviral agent for the treatment of HBV. Subsequently the group at Emory University headed by Dr. Dennis C. Liotta Dr. Woo-Baeg Choi and Dr. Raymond F. Schinazi developed a synthesis for the BCH-189 that gave exclusively the beta-diastereomers. They then went on to resolve the two enantiomers and demonstrated that the antiviral activity at non-toxic concentrations resided in the (−)-enantiomer, now called Lamivudine. Even though the Emory patents to lamivudine were invalidated in a USPTO Interference procedure, litigation on this dispute continued in US District Court. On June 6, 2002 in a joint press release GlaxoSmithKline, Shire Pharmaceuticals and Emory University announced a global settlement agreement that resolved all disputes relating to lamivudine and emtricitabine patent rights.  Under the terms of the settlement, Emory University received cash and a license to Shire’s emtricitabine patents and Shire and GSK received licenses to Emory’s lamivudine patents. The drug's effectiveness for treating HIV in combination with AZT was discovered accidentally when a patient took Zidovudine secretly while in a clinical trial of Lamivudine monotherapy. The drug was later licensed to the British pharmaceutical company Glaxo by Biochem Pharma (now Shire Pharmaceuticals) for a 14 percent royalty. GlaxoSmithKline subsequently ceded the product to its ViiV Healthcare joint venture in 2009.

- Jytdog (talk) 20:51, 27 February 2016 (UTC)

External links modified

Hello fellow Wikipedians,

I have just modified 3 external links on Lamivudine. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

• Added archive https://web.archive.org/web/20110928062844/http://us.gsk.com/products/assets/us_epivir.pdf to http://us.gsk.com/products/assets/us_epivir.pdf
• Added archive https://web.archive.org/web/20160304024056/https://www.aau.edu/WorkArea/DownloadAsset.aspx?id=2626 to https://www.aau.edu/WorkArea/DownloadAsset.aspx?id=2626
• Added archive https://web.archive.org/web/20120208231356/http://viivhealthcare.com/products/epivir-3tc.aspx?sc_lang=en to http://www.viivhealthcare.com/products/epivir-3tc.aspx?sc_lang=en

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

• If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
• If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 09:15, 16 December 2017 (UTC)